Stereotactic radiotherapy in epithelial ovarian cancer brain metastases patients

Journal of Ovarian Research

Krystyna Trela-Janus²  Jerzy Wydmański²  Krzysztof Składowski¹  Leszek Miszczyk²  Andrzej Tukiendorf³  Agata Celejewska² 

[1] Radiotherapy and Chemotherapy Clinic, Cancer Center and Institute of Oncology, 15 Wybrzeże AK Str., Gliwice, 44-101, Poland;Radiotherapy Department, Cancer Center and Institute of Oncology, 15 Wybrzeże AK Str., Gliwice, 44-101, Poland;Department of Epidemiology, Cancer Center and Institute of Oncology, 15 Wybrzeże AK Str., Gliwice, 44-101, Poland

关键词: Classification tree;    Survival analysis;    Risk factors;    Stereotactic radiotherapy;    Brain metastases;    Epithelial ovarian cancer;   

Others  :  1151810
DOI  :  10.1186/s13048-014-0079-1

 received in 2014-04-11, accepted in 2014-07-31,  发布年份 2014

【 摘 要 】

Background

In this report we present the results of the retrospective (survival and classification) analyses of possible prognostic factors prolonging survival in epithelial ovarian cancer brain metastases patients after stereotactic radiotherapy. We focus on a wide range of available predictors to establish survival in patients with a good health status and no more than three lesions.

Methods

Two parallel statistical methods in survival analysis were used: classical and Bayesian methods to verify statistical results. To display the predicted and posterior survivals, classification trees were built.

Results

From the initial set of prognostic factors, only four were established as statistically significant in multivariate regression. They were: survival to metastases to brain after epithelial ovarian cancer diagnosis, number of metastases at diagnosis, central nervous system radiotherapy prior to stereotactic radiotherapy, and interval to stereotactic radiotherapy after metastases diagnosis.

Conclusions

When considering evidence-based standards of treatment of patients suffering from epithelial ovarian cancer brain metastases, the established clinical factors are suggested to be prognostic.

【 授权许可】

   
2014 Celejewska et al.; licensee BioMed Central Ltd

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Mayer RJ, Berkowitz RS, Griffiths CT: Central nervous system involvement by ovarian carcinoma. A complication of prolonged survival with metastatic disease. Cancer 1978, 41:776-783.
• [2]Cohen ZR, Suki D, Weinberg JS, Marmor E, Lang FF, Gershenson DM, Sawaya R: Brain metastases in patients with ovarian carcinoma: prognostic factors and outcome. J Neuro-Oncol 2005, 66:313-325.
• [3]Pectasides D, Aravantinos G, Fountzilas G, Kalofonos C, Efstathiou E, Karina M, Pavlidis N, Farmakis D, Economopoulos T, Dimopoulos MA: Brain metastases from epithelial ovarian cancer. The Hellenic Cooperative Oncology Group (HeCOG) experience and review of the literature. Anticancer Res 2005, 25:3553-3558.
• [4]Pietzner K, Oskay-Oezcelik G, Khalfaoui K, Boehmer D, Lichtenegger W, Sehouli J: Brain metastases from epithelial ovarian cancer: overview and optimal management. Anticancer Res 2009, 29:2793-2798.
• [5]Chen YL, Cheng WF, Hsieh CY, Chen CA: Brain metastasis as a late manifestation of ovarian carcinoma. Eur J Cancer Care 2011, 20:44-49.
• [6]Hardy JR, Harvey VJ: Cerebral metastases in patients with ovarian cancer treated with chemotherapy. Gynecol Oncol 1989, 33:296-300.
• [7]Bruzzone M, Campora E, Chiara S, Giudici S, Merlini L, Simoni C, Mammoliti S, Rubagotti A, Rosso R: Cerebral metastases secondary to ovarian cancer: still an unusual event. Gynecol Oncol 1993, 49:37-40.
• [8]Chiang YC, Qiu JT, Chang CL, Wang PH, Ho CM, Lin WC, Huang YF, Lin H, Lu CH, Chou CY: Brain metastases from epithelial ovarian carcinoma: evaluation of prognosis and managements – a Taiwanese Gynecol Oncol Group (TGOG) study. Gynecol Oncol 2012, 125:37-41.
• [9]Micha JP, Goldstein BH, Hunter JV, Rettenmaier MA, Brown JV: Long-term survival in an ovarian cancer patient with brain metastases. Gynecol Oncol 2004, 92:978-980.
• [10]Pectasides D, Pectasides M, Economopoulos T: Brain metastases from epithelial ovarian cancer: a review of the literature. Oncologist 2006, 11:252-260.
• [11]Lee YK, Park NH, Kim JW, Song YS, Kang SB, Lee HP: Gamma-knife radiosurgery as an optimal treatment modality for brain metastases from epithelial ovarian cancer. Gynecol Oncol 2008, 108:505-509.
• [12]LeRoux PD, Berger MS, Elliott JP, Tamimi HK: Cerebral metastases from ovarian carcinoma. Cancer 1991, 67:2194-2199.
• [13]Cormio G, Maneo A, Parma G, Pittelli MR, Miceli MD, Bonazzi C: Central nervous system metastases in patients with ovarian carcinoma. A report of 23 cases and a literature review. Ann Oncol 1995, 6:571-574.
• [14]Geisler JP, Geisler HE: Brain metastases in epithelial ovarian carcinoma. Gynecol Oncol 1995, 57:246-249.
• [15]Sood A, Kumar L, Sood R, Sandhu MS: Epithelial ovarian carcinoma metastatic to the central nervous system: a report on two cases with review of literature. Gynecol Oncol 1996, 62:113-118.
• [16]Rodriguez GC, Soper JT, Berchuck A, Oleson J, Dodge R, Montana G, Clarke-Pearson DL: Improved palliation of cerebral metastases in epithelial ovarian cancer using a combined modality approach including radiation therapy, chemotherapy, and surgery. J Clin Oncol 1992, 10:1553-1560.
• [17]Cooper KG, Kitchener HC, Parkin DE: Cerebral metastases from epithelial ovarian carcinoma treated with carboplatin. Gynecol Oncol 1994, 55:318-323.
• [18]Anupol N, Ghamande S, Odunsi K: Evaluation of prognostic factors and treatment modalities in ovarian cancer patients with brain metastases. Gynecol Oncol 2002, 85:487-492.
• [19]Ratner ES, Toy E, O’Malley DM, McAlpine J, Rutherford TJ, Azodi M, Higgins SA, Schwartz PE: Brain metastases in epithelial ovarian and primary peritoneal carcinoma. Int J Gynecol Cancer 2009, 19:856-859.
• [20]Gadducci A, Tana R, Teti G, Fanucchi A, Pasqualetti F, Cionini L, Genazzani AR: Brain recurrences in patients with ovarian cancer: report of 12 cases and review of the literature. Anticancer Res 2007, 27:4403-4410.
• [21]Brown JV, Goldstein BH, Duma CM, Rettenmaier MA, Micha JP: Gamma-knife radiosurgery for the treatment of ovarian cancer metastatic to the brain. Gynecol Oncol 2005, 97:858-861.
• [22]Navarro-Martín A, Maitz A, Manders M, Ducharme E, Chen P, Grills I: Gamma knife radiosurgery as a primary treatment option for solitary brain metastases from ovarian carcinoma. Clin Transl Oncol 2009, 11:326-328.
• [23]Cox DR, Oakes D: Analysis of Survival Data. Chapman & Hall/CRC, Boca Raton; 1984.
• [24]A Language and Environment for Statistical Computing. R Version 3.0.2. R Foundation for Statistical Computing, Vienna; 2014.
• [25]Spiegelhalter D, Thomas A, Best N, Lunn D: WinBUGS. Version 1.4.3. Imperial College School of Medicine & Medical Research Council-Biostatistics Unit, Cambridge; 2003.
• [26]Breiman L, Friedman JH, Stone CJ, Olshen RA: Classification and Regression Trees. Chapman & Hall/CRC, Boca Raton; 1984.
• [27]Ripley B: Classification and Regression Trees. Version 1.0-35. R Foundation for Statistical Computing, Vienna; 2014.
• [28]Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, Kenjyo M, Oya N, Hirota S, Shioura H, Kunieda E, Inomata T, Hayakawa K, Katoh N, Kobashi G: Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 2006, 295:2483-2491.